表紙
市場調查報告書

糖尿病化驗:醫療設備的開發平台評估

Diabetes Assays - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 640305
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
糖尿病化驗:醫療設備的開發平台評估 Diabetes Assays - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年11月14日內容資訊: 英文 93 Pages
簡介

本報告提供全球糖尿病化驗 (糖尿病審定)的相關產品市場上之主要開發中產品及其臨床實驗的進展調查,同時彙整產品的功能、特性比較分析 (臨床實驗的各進展階段) ,及主要企業、組織的簡介及代表性產品,近來的市場動靜 (業績報告、資本交易趨勢等) 等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 糖尿病化驗概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期

第4章 糖尿病化驗:臨床實驗中的開發中產品,各企業

  • 糖尿病化驗的企業:各臨床實驗階段的開發中產品
  • 糖尿病化驗:各臨床實驗階段的開發中產品

第5章 糖尿病化驗市場:企業、產品概要

  • Abcodia Ltd
    • 開發中產品的資訊,現在進行中的臨床實驗概要
  • Adaptive Biotechnologies Corp
  • Alfa Wassermann Inc
  • AmideBio LLC
  • Aura Biotechnologies Pvt Ltd
  • Beckman Coulter Inc
  • Biocrates Life Sciences AG
  • Caprion Biosciences Inc
  • DaekiTech
  • Drexel University
  • ELITechGroup Inc
  • Enable Biosciences Inc
  • FibroStatin SL
  • Fujirebio Diagnostics Inc
  • Genalyte Inc
  • Genesis Detection Systems, Inc.
  • Helmholtz Centre for Infection Research
  • Hemex Health Inc
  • ImmusanT Inc
  • IntraMed Diagnostics, LLC
  • Janssen Diagnostics LLC
  • Johns Hopkins University
  • Mellitus LLC
  • Numares AG
  • Ortho-Clinical Diagnostics Inc
  • Peri Rx Inc
  • PortaScience Inc
  • Protagen AG
  • Queen Mary University of London
  • QuickCheck Health Inc
  • Shenzhen Mindray Bio-Medical Electronics Co Ltd
  • Singulex Inc
  • SomaLogic Inc
  • The Forsyth Institute
  • University of Canterbury
  • University of Colorado
  • University of Florida
  • University of Oxford
  • University of South Florida
  • Xhale Inc
  • Yaathum Biotech Pvt Ltd

第6章 糖尿病化驗市場:目前的趨勢 (共10件)

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0819EPD

GlobalData's Medical Devices sector report, "Diabetes Assays - Medical Devices Pipeline Assessment, 2019" provides an overview of Diabetes Assays currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Diabetes Assays pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Diabetes Assays under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Diabetes Assays and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Diabetes Assays under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Introduction 9

  • 2.1 Diabetes Assays Overview 9

3 Products under Development 10

  • 3.1 Diabetes Assays - Pipeline Products by Stage of Development 10
  • 3.2 Diabetes Assays - Pipeline Products by Segment 11
  • 3.3 Diabetes Assays - Pipeline Products by Territory 12
  • 3.4 Diabetes Assays - Pipeline Products by Regulatory Path 13
  • 3.5 Diabetes Assays - Pipeline Products by Estimated Approval Date 14

4 Diabetes Assays - Pipeline Products under Development by Companies 15

  • 4.1 Diabetes Assays Companies - Pipeline Products by Stage of Development 15
  • 4.2 Diabetes Assays - Pipeline Products by Stage of Development 17

5 Diabetes Assays Companies and Product Overview 19

  • 5.1 Abcodia Ltd Company Overview 19
    • 5.1.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.2 Adaptive Biotechnologies Corp Company Overview 20
    • 5.2.1 Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.3 Alfa Wassermann Inc Company Overview 21
    • 5.3.1 Alfa Wassermann Inc Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.4 AmideBio LLC Company Overview 22
    • 5.4.1 AmideBio LLC Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.5 Aura Biotechnologies Pvt Ltd Company Overview 23
    • 5.5.1 Aura Biotechnologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.6 Beckman Coulter Inc Company Overview 25
    • 5.6.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.7 Biocrates Life Sciences AG Company Overview 29
    • 5.7.1 Biocrates Life Sciences AG Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.8 Caprion Biosciences Inc Company Overview 31
    • 5.8.1 Caprion Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.9 DaekiTech Company Overview 33
    • 5.9.1 DaekiTech Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.10 Drexel University Company Overview 34
    • 5.10.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.11 ELITechGroup Inc Company Overview 35
    • 5.11.1 ELITechGroup Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.12 Enable Biosciences Inc Company Overview 37
    • 5.12.1 Enable Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.13 FibroStatin SL Company Overview 39
    • 5.13.1 FibroStatin SL Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.14 Fujirebio Diagnostics Inc Company Overview 40
    • 5.14.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.15 Genalyte Inc Company Overview 41
    • 5.15.1 Genalyte Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.16 Genesis Detection Systems, Inc. Company Overview 42
    • 5.16.1 Genesis Detection Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.17 Helmholtz Centre for Infection Research Company Overview 43
    • 5.17.1 Helmholtz Centre for Infection Research Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.18 Hemex Health Inc Company Overview 44
    • 5.18.1 Hemex Health Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.19 ImmusanT Inc Company Overview 45
    • 5.19.1 ImmusanT Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.20 IntraMed Diagnostics, LLC Company Overview 46
    • 5.20.1 IntraMed Diagnostics, LLC Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.21 Janssen Diagnostics LLC Company Overview 47
    • 5.21.1 Janssen Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.22 Johns Hopkins University Company Overview 48
    • 5.22.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.23 Mellitus LLC Company Overview 49
    • 5.23.1 Mellitus LLC Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.24 Numares AG Company Overview 50
    • 5.24.1 Numares AG Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.25 Ortho-Clinical Diagnostics Inc Company Overview 51
    • 5.25.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.26 Peri Rx Inc Company Overview 53
    • 5.26.1 Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.27 PortaScience Inc Company Overview 54
    • 5.27.1 PortaScience Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.28 Protagen AG Company Overview 55
    • 5.28.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.29 Queen Mary University of London Company Overview 56
    • 5.29.1 Queen Mary University of London Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.30 QuickCheck Health Inc Company Overview 57
    • 5.30.1 QuickCheck Health Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.31 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 58
    • 5.31.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.32 Singulex Inc Company Overview 60
    • 5.32.1 Singulex Inc Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.33 SomaLogic Inc Company Overview 61
    • 5.33.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.34 The Forsyth Institute Company Overview 62
    • 5.34.1 The Forsyth Institute Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.35 University of Canterbury Company Overview 63
    • 5.35.1 University of Canterbury Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.36 University of Colorado Company Overview 64
    • 5.36.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.37 University of Florida Company Overview 65
    • 5.37.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.38 University of Oxford Company Overview 66
    • 5.38.1 University of Oxford Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.39 University of South Florida Company Overview 67
    • 5.39.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.40 Xhale Inc Company Overview 68
    • 5.40.1 Xhale Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.41 Yaathum Biotech Pvt Ltd Company Overview 69
    • 5.41.1 Yaathum Biotech Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 69

6 Diabetes Assays- Recent Developments 70

  • 6.1 Aug 30, 2019: Discovery paves the way for earlier detection of type 1 diabetes 70
  • 6.2 Jul 30, 2019: Proteomics International : Quarterly business activities update 71
  • 6.3 Jul 25, 2019: EKF to highlight Lucica Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019 75
  • 6.4 Jul 22, 2019: Study finds common blood tests could predict diabetes 75
  • 6.5 Jun 05, 2019: Hamilton And Enable Biosciences Team Up to Automate Ultra-Sensitive Antibody Detection Assay Platform 76
  • 6.6 Jun 01, 2019: Greg Milosevich appointed President of Beckman Coulter Life Sciences 77
  • 6.7 May 14, 2019: Siemens Healthineers Hemoglobin A1c test for diagnosing and monitoring Diabetes now available on the Atellica Solution 77
  • 6.8 May 14, 2019: Ortho Clinical Diagnostics to host 4th Annual Hospital C-Suite Summit in Singapore 78
  • 6.9 Apr 24, 2019: Proteomics International Laboratories: Quarterly business update for the year 2019 78
  • 6.10 Apr 01, 2019: Mologic expands US and UK operations 81

7 Appendix 90

  • 7.1 Methodology 90
  • 7.2 About GlobalData 93
  • 7.3 Contact Us 93
  • 7.4 Disclaimer 93

List of Tables

  • Table 1: Diabetes Assays - Pipeline Products by Stage of Development 10
  • Table 2: Diabetes Assays - Pipeline Products by Segment 11
  • Table 3: Diabetes Assays - Pipeline Products by Territory 12
  • Table 4: Diabetes Assays - Pipeline Products by Regulatory Path 13
  • Table 5: Diabetes Assays - Pipeline Products by Estimated Approval Date 14
  • Table 6: Diabetes Assays Companies - Pipeline Products by Stage of Development 15
  • Table 7: Diabetes Assays - Pipeline Products by Stage of Development 17
  • Table 8: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 9: Molecular Biomarker - Diabetes - Product Status 19
  • Table 10: Molecular Biomarker - Diabetes - Product Description 19
  • Table 11: Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 12: Pre - Symptomatic Biomarker - Type 1 Diabetes - Product Status 20
  • Table 13: Pre - Symptomatic Biomarker - Type 1 Diabetes - Product Description 20
  • Table 14: Alfa Wassermann Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 15: ACE Alera Clinical Chemistry System - Direct A1c Assay - Product Status 22
  • Table 16: ACE Alera Clinical Chemistry System - Direct A1c Assay - Product Description 22
  • Table 17: AmideBio LLC Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 18: Diagnostic Test - T1 Diabetes - Product Status 23
  • Table 19: Diagnostic Test - T1 Diabetes - Product Description 23
  • Table 20: Aura Biotechnologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 21: AURA Quant Glargine ELISA Kit - Product Status 24
  • Table 22: AURA Quant Glargine ELISA Kit - Product Description 24
  • Table 23: AURA Quant Human C-peptide Kit - Product Status 24
  • Table 24: AURA Quant Human C-peptide Kit - Product Description 25
  • Table 25: AURA Quant Human Insulin ELISA Kit - Product Status 25
  • Table 26: AURA Quant Human Insulin ELISA Kit - Product Description 25
  • Table 27: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 28: AU480 Clinical System - Next Generation HbA1c Assay - Product Status 26
  • Table 29: AU480 Clinical System - Next Generation HbA1c Assay - Product Description 27
  • Table 30: AU5810 Clinical System - Next-generation HbA1c Assay - Product Status 27
  • Table 31: AU5810 Clinical System - Next-generation HbA1c Assay - Product Description 27
  • Table 32: AU5820 Clinical System - Next-generation HbA1c Assay - Product Status 27
  • Table 33: AU5820 Clinical System - Next-generation HbA1c Assay - Product Description 28
  • Table 34: AU5830 Clinical System - Next-generation HbA1c Assay - Product Status 28
  • Table 35: AU5830 Clinical System - Next-generation HbA1c Assay - Product Description 28
  • Table 36: AU5840 Clinical System - Next-generation HbA1c Assay - Product Status 28
  • Table 37: AU5840 Clinical System - Next-generation HbA1c Assay - Product Description 29
  • Table 38: AU680 Clinical System - Next-generation HbA1c Assay - Product Status 29
  • Table 39: AU680 Clinical System - Next-generation HbA1c Assay - Product Description 29
  • Table 40: Biocrates Life Sciences AG Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 41: Diagnostic Assay - Type 2 Diabetes - Product Status 30
  • Table 42: Diagnostic Assay - Type 2 Diabetes - Product Description 30
  • Table 43: Metabolomic Biomarker Assay - Diabetes - Product Status 31
  • Table 44: Metabolomic Biomarker Assay - Diabetes - Product Description 31
  • Table 45: Caprion Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 46: Diagnostic Assay - Gestational Diabetes Progression - Product Status 32
  • Table 47: Diagnostic Assay - Gestational Diabetes Progression - Product Description 32
  • Table 48: Diagnostic Assay - Islet Cell Health - Product Status 34
  • Table 49: Diagnostic Assay - Islet Cell Health - Product Description 34
  • Table 50: DaekiTech Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 51: Diagnostic Kit - Diabetes - Product Status 35
  • Table 52: Diagnostic Kit - Diabetes - Product Description 35
  • Table 53: Drexel University Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 54: Diagnostic Assay - Diabetic Ulcers - Product Status 36
  • Table 55: Diagnostic Assay - Diabetic Ulcers - Product Description 36
  • Table 56: ELITechGroup Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 57: Eon 100 Automated Chemistry Analyzer - Hemoglobin A1c Assay - Product Status 37
  • Table 58: Eon 100 Automated Chemistry Analyzer - Hemoglobin A1c Assay - Product Description 37
  • Table 59: Eon 300 Automated Chemistry Analyzer - Hemoglobin A1c Assay - Product Status 39
  • Table 60: Eon 300 Automated Chemistry Analyzer - Hemoglobin A1c Assay - Product Description 39

List of Figures

  • Figure 1: Diabetes Assays - Pipeline Products by Stage of Development 10
  • Figure 2: Diabetes Assays - Pipeline Products by Segment 11
  • Figure 3: Diabetes Assays - Pipeline Products by Territory 12
  • Figure 4: Diabetes Assays - Pipeline Products by Regulatory Path 13
  • Figure 5: Diabetes Assays - Pipeline Products by Estimated Approval Date 14